Therapeutic window for 5-HT reuptake inhibitors by PITCHOT, William et al.
689
Role of omental milky spots in the local
immune response
SIR,-Dr Koten and Professor den Otter’s hypothesis (Nov 9,
p 1189) concerning omental milky spots and Dr Shimotsuma and
Dr Simpson-Morgan’s (Dec 28, p 1596) subsequent
correspondence require comment. First I would emphasise that this
hypothesis was proposed at the 4th international symposium on the
biology, immunology, and surgery of the greater omentum in May,
1991.1 At this congress my colleagues and I introduced the term
omentum-associated lymphoid tissue (OALT) for the milky spots,2
which we published in two reports in 1991.3,4 Our data on milky
spots in animals (distinct T-cell area, distinct B-cell area, specific
macrophage subsets, specific reaction after immunisation) were the
basis of these papers. Moreover, we have shown conclusively that
precursor cells of the macrophage lineage can localise in and
proliferate in the mouse milky spots,S indicating that milky spots are
a source of free peritoneal macrophages. We have lately identified,
as did Shimutsoma and Simpson-Morgan, human milky spots.
They contain mainly macrophages.6 Since, however, no T-cell or
B-cell areas (apart from some isolated T and B cells) were found, we
did not see any evidence for Koten and den Otter’s hypothesis.
Additionally, in man the introduction of the term OALT for milky
spots is not supported by the data of Shimutsoma et aF who
reported that "the lymphocytes did not show any preferential
location within the milky spots". We do, on the other hand, agree
that human milky spots are important for the immunity of the
peritoneal cavity, especially during inflammation. Milky spots then
provide activated macrophages, which may play a key part against
bacterial. infection and tumour cell growth.
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Therapeutic window for 5-HT reuptake
inhibitors
SIR,-Fichtner et aP suggested a therapeutic window for
fluoxetine to explain the induction of suicidal thoughts in patients
treated with this antidepressant drug. They reported two cases of
depressive relapse in patients receiving fluoxetine doses higher than
that associated with the best antidepressant effect. We report a
similar observation with fluvoxamine, another potent inhibitor of
presynaptic serotonin reuptake.
A 32-year-old woman presented with DSM-III-R criteria for an
obsessive-compulsive disorder without major depression. She had
no suicidal thoughts and no history of suicide attempts and late
luteal phase syndrome. She was started on fluvoxamine (200 mg per
day) and two months later showed great improvement of obsessive-
compulsive symptoms and an important but incomplete reduction
in both somatic and psychic anxiety. The dose of fluvoxamine was
then increased to 250 mg. One week later, the patient had severe
symptoms of generalised anxiety with a score of 33 on the Hamilton
anxiety scale,2 panic attacks, and major suicidal tendencies, without
change in obsessive-compulsive symptoms. Akathisia or depressive
psychopathology did not develop. The dose of fluvoxamine was
then reduced to 200 mg, with, a few days later, remission of anxiety
symptoms (Hamilton anxiety scale score 8), and a decrease in
frequency and intensity of both panic attacks and suicidal thoughts.
Ten days after the reduction of fluvoxamine dose to 200 mg, the
treatment was discontinued with total disappearance of suicidal
ideation after five days. However, the patient had progressively
worsening anxiety symptoms, which led to the reintroduction of
fluvoxamine (200 mg per day) three weeks later, with rapid
remission.
This report describes the emergence of suicidal thoughts in a
non-depressed patient treated with fluvoxamine for an obsessive-
compulsive disorder. These suicidal tendencies without any
concurrent akathisia or depressive psychopathology appeared at a
dose higher than the optimum for effective control of obsessive-
compulsive and anxious symptoms, suggesting a therapeutic
window for fluvoxamine. Teicher et aP previously reported similar
induction of suicidal ideation with fluoxetine, also in doses well
above the recommended 20 mg daily dose-ie, 40-80 mg (in 5 of 6
patients). 3
This observation suggests that particular caution is needed in the
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PTH(1-84) in hypercalcaemia of malignancy
SIR,-Dr Ratcliffe and colleagues (Jan 18, p 164) report the role
of parathyroid-hormone-related protein (PTHrP) in the
investigation of hypercalcaemia. They emphasise the importance of
PTHrP in humoral hypercalcaemia of malignancy and the part that
biochemical detection of this peptide will play in diagnosing the
cause of hypercalcaemia. The diagnostic value of PTH (1-84),
however, in the detection of a non-parathyroid cause for
hypercalcaemia may be understated. In hypercalcaemia of
malignancy most workers find that PTH(1-84) is above the limit of
assay detection in less than 25% of cases.1-3 Those patients with
detectable PTH(1-84) rarely have the high values seen in primary
hyperparathyroidism. It seems from Ratcliffe and colleagues’ figure
that in patients with solid tumours (gpA) none had PTH(1-84)
greater than the lowest value obtained in those patients with proven
primary hyperparathyroidism (3-0 pmol/1). If the cut-off value of
less than 3-0 pmol/1 PTH is used in identifying patients with solid
tumours associated with hypercalcaemia the sensitivity obtained
will be much improved. PTH(1-84) values in hypercalcaemia of
malignancy can be raised by calcium lowering therapy, and so it is
important to obtain samples for measurement of PTH(1-84) early
in a patient’s admission.4 It would be interesting to know how in
Ratcliffe and colleagues’ study the serum calcium values altered in
the second sample obtained in the 121 patients who remained
hypercalcaemic and whether PTH(1-84) was measured on the
admission or subsequent sample.
PTHrP assays will have an important part to play in the diagnosis
and management of hypercalcaemia, but they are not freely
available at present and will be costly when commercially available.
Used wisely, PTH(1-84) assays can establish the diagnosis or
exclude the incorrect diagnosis in most cases of hypercalcaemia.
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